Long-term Prognostic Value of Asymptomatic Cardiac Troponin T Elevations in Patients After Major Vascular Surgery  by Kertai, M.D et al.
Long-term Prognostic Value of Asymptomatic
Cardiac Troponin T Elevations in Patients After
Major Vascular Surgery
M. D. Kertai,1 E. Boersma,1 J. Klein,2 H. van Urk,3 J. J. Bax1 and D. Poldermans3*
Departments of 1Cardiology, 2Anaesthesiology, and 3Vascular Surgery, Erasmus Medical Center, Rotterdam,
The Netherlands
Background. Cardiac troponin T (cTnT) is a sensitive and specific marker for myocardial injury, but elevations of cTnT
without clinical evidence of ischemia and persistent or new electrocardiographic (ECG) abnormalities are common in
patients undergoing major vascular surgery. We explored the long-term prognostic value of cTnT levels in these patients.
Methods. A follow-up study was conducted between 1996–2000 in 393 patients who underwent successful aortic or
infrainguinal vascular surgery and routine sampling of cTnT. Patients were followed until May 2003 (median of 4 years
[25th–75th percentile, 2.8–5.3 years]). Total creatine kinase (CK), CK-MB, and cTnT were routinely screened in all
patients, and included sampling after surgery and the mornings of postoperative days 2, 3 and 7. Electrocardiograms were
also routinely evaluated for sign of ischemia. An elevated cTnTwas defined as serum concentrations $0.1 ng/ml in any of
these samples. All-cause mortality was evaluated during long-term follow-up.
Results. Eighty patients (20%) had late death. The incidence of all-cause mortality (41% vs. 17%; p , 0.001) was
significantly higher in patients with an elevated cTnT level compared to patients with normal cTnT. After adjustment for
baseline clinical characteristics, the association between an elevated cTnT level and increased incidence of all-cause mortality
(adjusted hazard ratio, 1.9; 95% CI, 1.1–3.1) persisted. Elevated cTnT had significant prognostic value in patients with and
without renal dysfunction, abnormal levels of CK-MB, and in patients with transient ECG abnormalities.
Conclusions. Elevated cTnT levels are associated with an increased incidence of all-cause mortality in patients undergoing
major vascular surgery.
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Introduction
In patients undergoing major vascular surgery myo-
cardial ischemia is the most common cause of
perioperative and late morbidity and mortality.1 – 4
However, symptoms of myocardial ischemia may be
masked by perioperative use of sedative and analgesic
drugs, and detection of perioperative myocardial
ischemia may be hampered by false positive elevations
of MB creatine kinase levels attributed to skeletal
muscle injury occurring during surgery.5 Recently,
cardiac troponins have emerged as new risk stratifica-
tion tools for prediction of perioperative and short-
term cardiac complications. Cardiac troponins (T or I)
are highly sensitive and specific markers for myocar-
dial injury.6 It has been shown that routine surveil-
lance for cardiac troponins can be useful for
identifying patients without clinical evidence of
myocardial ischemia who are at increased risk of
perioperative myocardial infarction and death.5,7 – 9
However, these studies are limited by relatively small
numbers of patients, mixture of surgical populations,
and by a short duration of follow-up. Accordingly, the
aim of the present study was to explore the long-term
prognostic value of cardiac troponin T (cTnT) levels
after successful major vascular surgery in patients
without clinical evidence of ischemia or new electro-
cardiographic changes consistent with ischemia.
Methods
Study population
We retrospectively reviewed the hospital electronic
database for all patients who underwent major
vascular surgery between May 1996 and December
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2000 at the Erasmus Medical Center, Rotterdam, the
Netherlands. This database holds information on
demographic data, clinical records, and information
on the perioperative course of all patients. During this
period, the hospital protocol recommended serial
blood sampling for cardiac enzymes and electrocar-
diograms (day 2, 3 and 7 or discharge) in patients
undergoing major vascular surgery. As a result of this
protocol serial sampling of cardiac enzymes and
electrocardiograms were taken in 402 consecutive
patients who underwent major vascular surgery. Of
these 402 patients, nine patients with elevated cTnT
died or developed non-fatal myocardial infarction
after surgery and subsequently were excluded from
the analyses. The remaining 393 patients who survived
at least 30 days after surgery formed the base of the
present study.
Measurement of CK, CK-MB, and cardiac troponin T
Total creatine kinase and creatine kinase MB activities
were measured until December 1998 (n ¼ 242 patients)
by means of a N-acetylcysteine-activated optimised
ultraviolet test (Merck; Darmstadt, Germany). Cre-
atine kinase MB activity was determined by immu-
noinhibition. After December 1998, a mass assay for
CK and CK-MB, utilizing a monoclonal antibody, was
performed on the Roche/Hitachi 747 analyser. The
upper levels of the reference intervals of CK was
190 IU/L, and for CK-MB activity above 24 IU/L, or
the CK-MB activity fraction exceeding 6% of total CK.
Cardiac troponin T during the entire study period
was measured qualitatively using a whole blood rapid
test (TropT version 2, Roche Diagnostics, Mannheim,
Germany).10 The cut-off value for an abnormal cTnT
test result was $0.1 ng/ml.
Data collection
The computerized hospital database, medical files,
nurses reports, surgical records, postoperative charts,
discharge letters and records of the outpatient clinic
visits were manually screened to collect information
on the presence of clinical risk factors and chronic
cardiac medication use. Medical records were
screened for the following clinical risk factors includ-
ing age, gender, current or prior stable angina,
previous MI, congestive heart failure, chronic pul-
monary disease, renal dysfunction, diabetes mellitus,
stroke, and hypertension. Additionally, postoperative
12-lead electrocardiograms were evaluated for
abnormalities consistent with sign of ischemia, myo-
cardial infarction or conduction abnormalities.
Follow-up
In May 2003 a follow-up was performed of all 393
patients who survived major vascular surgery for at
least 30 days. The primary endpoint chosen for the
present study was all-case mortality in order to avoid
misclassification among cardiac, arrhythmic and non-
cardiac mortality. Information about patients’ vital
status was requested by approaching the Office of
Civil Registry. For patients who died at the Erasmus
MC during follow-up, hospital records and autopsy
results were retrieved and reviewed. For patients who
died outside of Erasmus MC, general practitioners
were approached to ascertain the cause of death. If no
autopsy was performed, medical information pro-
vided by general practitioners was used to ascertain
the cause of death.
Statistical analysis
Dichotomous variables were compared by means of
Fisher’s exact test, and continuous variables were
compared by means of Kruskal–Wallis test. The
Kaplan–Meier method was used to evaluate the
prognostic value of cTnT with respect to event-free
survival. Differences in survival curves were com-
pared by the log-rank test. Univariable Cox pro-
portional hazard regression models were used to
assess the independent association between cTnT,
baseline clinical characteristics, and all-cause mor-
tality. In order to avoid model over-fitting we applied a
clinical risk model (3) that was developed elsewhere,
and the clinical risk assessment was summarized in
one index variable. Multivariable regression models
were constructed by backward stepwise deletion of
the least significant characteristics. Hazard ratios
(HRs) and corresponding 95% confidence intervals
(CIs) are reported. For all tests, a P value of ,0.05 was
considered significant. All analyses were performed
using SPSS statistical software (SPSS Inc., Chicago,
Illinois, version 11.0).
Results
Patient characteristics
The characteristics of the study population are
described in Table 1. Fourteen percent of patients
had elevated ($0.1 ng/ml) cTnT levels postopera-
tively. Patients with abnormal cTnT levels were older,
more often had a history of angina pectoris, renal
dysfunction, and more often underwent acute or
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elective abdominal aortic aneurysm repair than
patients with normal cTnT levels (Table 1). Further-
more, calcium-channel blocker and nitrate use, elev-
ated serum creatinine levels, abnormal elevations of
postoperative creatine kinase and creatine kinase MB
isoenzyme, and abnormal electrocardiograms were
also more often observed in patients with abnormal
levels of cTnT compared to patients with normal levels
of cTnT (Table 1).
Follow-up
The median follow-up was 4.3 years (25th–75th
percentile, 2.8–5.3 years). Eighty (20%) patients died
during follow-up, among whom 49 died of cardiac
causes. The cause of non-cardiac death was respiratory
insufficiency in 10, cancer 10, sepsis secondary to
infected prosthetic grafts seven, renal failure two and
other causes in two. Additionally, five (1.3%) patients
had late coronary revascularization because of pro-
gression of angina pectoris, six patients suffered a non-
fatal cerebrovascular accident, and there were five
patients who developed symptoms of congestive heart
failure.
Relation between abnormal cTnT levels and long-term
outcome
Survival of patients with abnormal and normal cTnT
levels is shown in Fig. 1. Abnormal levels of cTnT were
associated with a significant increased risk of all-cause
mortality in univariable analysis. Compared with
Table 1. Baseline characteristics
Characteristics Cardiac troponin T level P-value*
Abnormal† n ¼ 54; (%) Normal n ¼ 339; (%)
Demographics
Age $70 years 34 (63) 154 (45) 0.02
Male sex 45 (83) 268 (79) 0.60
Medical history
Current stable or history of angina pectoris 23 (43) 65 (19) 0.001
Previous myocardial infarction 22 (41) 102 (30) 0.15
Congestive heart failure 4 (7) 14 (4) 0.29
Diabetes mellitus 6 (11) 46 (14) 0.83
Prior cerebrovascular accident 6 (11) 45 (13) 0.82
Renal dysfunction 16 (30) 42 (12) 0.003
Chronic pulmonary disease 15 (28) 68 (20) 0.21
Hypertension 23 (43) 132 (39) 0.65
Prior CABG 6 (11) 34 (10) 0.81
Prior PTCA 1 (2) 14 (4) 0.70
Type of surgery 0.04
Acute abdominal aortic repair 6 (11) 11 (3)
Thoracoabdominal aneurysm repair 2 (4) 12 (4)
Abdominal aortic aneurysm repair 25 (46) 131 (39)
Aortoiliac repair 9 (17) 51 (15)
Infrainguinal bypass 12 (22) 134 (40)
Chronic cardiac medication
ACE inhibitors 24 (44) 127 (38) 0.37
Aspirin 25 (46) 133 (39) 0.37
b-blockers 30 (56) 169 (50) 0.47
Ca-channel blockers 20 (37) 59 (17) 0.02
Nitrates 21 (39) 49 (15) ,0.001
Statins 21 (39) 137 (40) 0.88
Electrocardiogram
Left ventricular hypertrophy 14 (26) 59 (14) 0.14
Q waves consistent with previous myocardial infarction 12 (23) 38 (11) 0.03
ST-segment changes consistent with ischemia 15 (28) 45 (13) 0.007
Laboratory findings
Serum creatinine, mmol/L [median, IQR] 98.5 [80.8–143.5] 82 [67–104] ,0.001
Abnormal levels of creatine kinase 30 (56) 108 (32) 0.001
Abnormal levels of creatine kinase, MB isoenzyme 9 (17) 22 (7) 0.03
*Fisher exact two-sided test, or Kruskal–Wallis test.
†All data are presented as number (percentage) unless otherwise indicated; IQR, indicates interquartile range; CABG, coronary artery bypass
surgery; PTCA, percutaneous transluminal coronary angioplasty; For definition of risk factors see Section 2.
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patients with normal cTnT levels, patients with
abnormal cTnT levels had a more than two-fold
increase in risk of all-cause mortality (crude HR, 2.4;
95% CI, 1.5–4.0). Other variables that were associated
with all-cause mortality in our dataset included
chronic pulmonary disease and type of surgery.
Patients who underwent acute abdominal aortic
repair, thoracoabdominal and abdominal aortic aneur-
ysm repairs had relatively high long-term mortality
rates (Table 2). In contrast, aspirin, b-blocker and statin
use were associated with reduced all-cause mortality.
Additionally, no association was observed between
abnormal CK-MB levels and long-term mortality. The
association between increased cTnT levels and the
incidence of all-cause mortality persisted in multi-
variable analyses after correcting for other clinical risk
factors, and electrocardiographic changes consistent
with myocardial ischemia (Table 3). In separate
analyses we also studied the prognostic value of
cTnT levels in different subgroups of patients. There
were no significant differences observed in the prog-
nostic value of abnormal cTnT levels in subgroup of
patients with renal dysfunction, elevated levels of CK-
MB or in patients with ischemic ST-segment changes
on electrocardiogram (Table 4).
Prognostic value of cTnT levels according to cardiac risk
factors
Based on the number of cardiac risk factors and the
presence of abnormal cTnT levels the incidence of all-
cause mortality was estimated. If patients had a risk
index of 0 no patients had abnormal cTnT levels and
the incidence of all-cause mortality was 6.1% in
patients with normal cTnT (Fig. 2). In contrast, patients
with a risk index of 1 to 2, or $3 risk factors who had
abnormal cTnT levels were at substantially higher risk
of adverse perioperative outcome compared to
patients with normal cTnT levels.
Discussion
Asymptomatic cTnT elevations were associated with
an almost two-fold increased risk of long-term
mortality in patients undergoing successful major
vascular surgery, independent of the presence of risk
factors for coronary artery disease, renal dysfunction,
cardiac medication use, elevated CK-MB levels and
ST-changes consistent with myocardial ischemia.
These findings are consistent with the results of
previous studies on cardiac troponins as markers of
Fig. 1. Kaplan–Meier estimates of all-cause mortality according to normal and elevated levels of cardiac troponin T.
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myocardial injury in non-cardiac surgery setting.
Several investigations have shown that abnormal
levels of cardiac troponins identify patients at
increased risk of perioperative and short-term cardiac
complications.5,7 – 9 Lopez-Jimenez et al.9 showed that
abnormal levels of cTnT in patients undergoing non-
cardiac surgery was associated with a more than four-
fold increased risk of cardiac events during a 6 months
follow-up period. Kim et al. later confirmed these
findings,7 in 229 patients who underwent serial
measurements of cardiac troponin I levels after
vascular surgery. Twenty-eight (12%) patients had
abnormal postoperative cardiac troponin I levels,
which was associated with a six-fold increased risk
of 6 months mortality. In a more recent study similar
to our findings, Landesberg et al., also found a posi-
tive association between abnormal levels of cardiac
troponin I after vascular surgery and all-cause
mortality during on average of two and half years of
follow-up.11
Patients undergoing non-cardiac surgery with or at
high risk of coronary artery disease have an incidence
of perioperative myocardial ischemia exceeding 40%
with an associated nine-fold increased risk for cardiac
death and myocardial infarction.12,13 Patients with
events related to myocardial ischemia and surviving
the perioperative period still remain at high risk for
long-term cardiac complications.14 In this regard,
patients undergoing major vascular surgery are
particularly at very high risk for perioperative and
long-term mortality and morbidity related to myocar-
dial ischemia.2,15 – 17 Detection of myocardial ischemia
during and after major vascular surgery could be
difficult as a result of altered pain perception, false
Table 2. Univariable predictors and estimated risk of long-term all-cause mortality
Variables* Unadjusted P-value
Patients who died, n (%) HR (95% CI)
Demographics
Age $70 years 46 (24.5) 1.6 (1.0–2.4) 0.05
Male gender 64 (20.4) 1.1 (0.6–1.8) 0.82
Medical history
Current stable or history of angina pectoris 24 (27.3) 1.3 (0.8–2.2) 0.20
Previous myocardial infarction 30 (24.2) 1.3 (0.8–2.1) 0.22
Congestive heart failure 6 (33.3) 1.9 (0.8–4.3) 0.15
Diabetes mellitus 11 (21.2) 1.1 (0.6–2.2) 0.67
Prior cerebrovascular accident 14 (27.5) 1.6 (0.9–3.0) 0.10
Renal dysfunction 13 (22.4) 1.3 (0.7–2.3) 0.43
Chronic pulmonary disease 26 (31.3) 1.7 (1.1–2.8) 0.02
Hypertension 33 (21.2) 1.0 (0.7–1.6) 0.90
Medical history
Prior CABG 10 (25.0) 1.1 (0.5–2.1) 0.85
Previous PTCA 1 (6.7) 0.4 (0.1–2.6) 0.31
Type of surgery, compared with infrainguinal bypass 20 (13.7)
Acute abdominal aortic repair 6 (35.3) 3.8 (1.5–9.6) 0.004
Thoracoabdominal aneurysm surgery 7 (50.0) 6.5 (2.7–15.5) ,0.001
Abdominal aortic aneurysm repair 40 (25.6) 1.9 (1.1–3.3) 0.01
Aortoiliac repair 7 (11.7) 0.8 (0.3–1.8) 0.60
Chronic cardiac medication
ACE-inhibitors 30 (20.0) 0.9 (0.6–1.4) 0.70
Aspirin 23 (14.6) 0.6 (0.4–0.9) 0.03
b-blockers 34 (17.1) 0.7 (0.4–1.0) 0.05
Ca-channel blockers 19 (24.1) 1.0 (0.6–1.7) 0.95
Nitrates 20 (28.6) 1.5 (0.9–2.6) 0.10
Statins 14 (8.9) 0.3 (0.2–0.5) ,0.001
Electrocardiogram
Left ventricular hypertrophy 20 (27.4) 1.7 (1.0–2.8) 0.05
Q waves consistent with previous MI 13 (26.0) 1.3 (0.7–2.7) 0.40
ST segment changes consistent with ischemia 17 (28.3) 1.6 (0.9–2.8) 0.08
Laboratory findings
Abnormal CK-MB/CK index 8 (25.8) 1.6 (0.7–3.4) 0.20
Abnormal cardiac troponin T 22 (40.7) 2.4 (1.5–4.0) 0.001
*For definition of risk factors and laboratory findings see Section 2; HR, hazard ratio; CI, confidence interval.
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positive elevations of CK-MB levels or due to presence
of pre-existing electrocardiographic abnormalities.18
Cardiac troponins, on the other hand may help to
identify patients at increased risk for perioperative
and short-term adverse events. It contrast, it has been
observed that many patients without cardiac compli-
cations or symptoms related to myocardial ischemia
may have elevated cTnT levels,8 raising the question
whether or not these abnormal values are false
positive results, or indeed evidence of asymptomatic
myocardial injury. The findings of our study provide
evidence that asymptomatic patients with elevated
cTnT levels remain also at increased risk for long-term
mortality.
In earlier reports it was described that renal
dysfunction may interfere with the prognostic value
of cTnT because of its clearance may be decreased. In
contrast, Aviles et al.19 showed that cTnT levels
predicted short-term prognosis in acute coronary
syndrome patients regardless of the presence or
absence of renal dysfunction. Consistent with these
findings we found that abnormal cTnT levels inde-
pendently predicted long-term all-cause mortality
regardless of renal dysfunction. Similarly to previous
studies the prognostic value of abnormal cTnT levels
was superior to that of CK-MB elevations. In fact,
patients with abnormal cTnT levels experienced
adverse long-term mortality more often than patients
with elevated CK-MB levels.8,9,20 – 22 These data are
consistent with findings for surgical and non-surgical
populations indicating that abnormal cTnT levels is a
marker for myocardial injury, even if that myocardial
injury is not sufficient to cause CK-MB release and
clinical symptoms. Furthermore, the findings of our
study indicate that abnormal levels of cTnT indepen-
dently predicted long-term mortality in patients with
and without ECG abnormalities. These results are
consistent with the hypothesis that elevated cTnT
levels in these patients may reflect a degree of
myocardial ischemia, which is not sufficient to cause
ECG abnormalities that would be detected by routine
12-lead ECG recordings.9 These findings indicate that
cTnT may further facilitate identification of high-risk
patients.
The relationship between elevated levels of cardiac
troponin and incidence of cardiac complications may
help to guide risk stratification practices. As a screen-
ing test, cardiac troponins have been shown to
improve clinical management and subsequently
improve survival of patients presenting to the emer-
gency room with acute chest pain.23 Recently, a
marked reduction in adverse cardiac events were
Table 3. Multivariable predictors and estimated risk of long-term
all-cause mortality ðN 5 393Þ
Variables* Adjusted P-value
HR (95% CI)
Abnormal cardiac Troponin T 1.9 (1.1–3.1) 0.02
ST segment changes consistent with
ischemia
1.8 (1.0–3.1) 0.05
Risk factors,† compared with no risk factors
$ 3 5.5 (1.8–16.5) 0.002
1–2 2.8 (1.0–8.1) 0.05
Type of surgery, compared with
infrainguinal bypass
Acute abdominal aortic repair 2.4 (0.8–7.0) 0.1
Thoracoabdominal aneurysm surgery 8.5 (3.4–20.1) ,0.001
Abdominal aortic aneurysm repair 2.4 (1.4–4.3) 0.003
Aortoiliac repair 1.3 (0.5–3.2) 0.6
Chronic cardiac medication
Statins 0.3 (0.2–0.5) ,0.001
b-blockers 0.5 (0.3–0.8) 0.004
Aspirin 0.6 (0.3–0.9) 0.04
*For definition of variables see Section 2; HR, hazard ratio; CI,
confidence interval.
†Risk score was composed by assigning one point to each of the
following characteristics: age $70 years, angina pectoris, prior
myocardial infarction, heart failure, prior cerebrovascular event,
diabetes mellitus, renal dysfunction and chronic pulmonary disease.
Table 4. Prognostic value of abnormal cTnT levels according to subgroups of patients
Abnormal cTnT Normal cTnT HR (95% CI) Abnormal cTnT Normal cTnT HR (95% CI) P for interaction*
Normal renal function Renal dysfunction
Total 38 297 16 42
Death 18 (47.4%) 49 (16.5%) 3.0 (1.8–5.2) 4 (25%) 9 (21.4%) 0.9 (0.3–3.3) 0.08
Normal CK-MB levels Abnormal CK-MB levels
Total 44 304 9 22
Death 19 (43.2%) 50 (16.4%) 2.6 (1.6–4.5) 3 (33.4%) 5 (22.7%) 1.4 (0.3–5.9) 0.23
No ST segment changes ST segment changes
Total 37 294 15 45
Death 14 (37.8%) 48 (16.3%) 2.1 (1.1–3.8) 7 (46.7%) 10 (22.3%) 2.1 (0.8–5.4) 0.98
Numbers may not add up to 393 due to missing data; HR, hazard ratio; CI, confidence interval.
*P value for interaction represents a level of statistical evidence for heterogeneity in the prognostic value of cTnT in subgroup of patients with
renal dysfunction, abnormal levels of CK-MB and ST segment changes on electrocardiograms consistent with ischemia.
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reported among patients with elevated cardiac tropo-
nins and acute coronary syndromes if they were
randomized to an early invasive treatment.24 Our
data suggest that the perioperative measurement of
cTnT may have clinical utility for developing optimal
treatment strategies.
Several limitations of this study should be con-
sidered when interpreting the results. Since this study
was observational, adverse outcome events could
potentially have been missed. However, we used all
cause specific mortality data as the primary outcome
measure for this study. Additionally, during the study
period a qualitative test was used for detecting
elevated levels of cTnT, which did not allow us to
investigate the relation between different cTnT levels
and incidence of cardiac complications.
In conclusion, abnormal levels of cTnT after
successful major vascular surgery are associated with
a higher incidence of long-term all-cause mortality,
and provide additional prognostic information to
clinical risk factors and CK-MB levels. Clinical studies
are required to determine the most optimal approach
and management for patients with abnormal cTnT
levels to improve their long-term outcome.
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